The aim of the study is to collect post marketing safety data on IMOVAX Polio vaccine in China.

Objective:

To describe serious adverse events 30 days after each dose of IMOVAX Polio™ administered at 2, 3, and 4 months of age among infants living in the study cities of China.

Each study participant will receive an IMOVAX Polio™ injections at 2, 3 and 4 months of age (total of 3 doses) and will be followed up for 30 days after each vaccination.

Inclusion Criteria:

• Subject is 2 months of age or older (60-89days) when receiving the first dose of polio vaccine.
• Subject's parent /legal representative showed willingness to complete the 3 primary doses fully using IMOVAX Polio according to the schedule. one injection at 2, 3, 4 months old respectively;
• Informed consent form obtained by the subject's parent/legal representative.
• Subject plan to live in the selected study sites for at least three months after inclusion.

Exclusion Criteria:

• Subject with a history of serious illness (i.e., hypersensitivity, seizure, convulsion, encephalopathy diseases, etc.)
• Acute medical illness with or without fever within the last 72 hours.
• Vaccination planned in the 4 weeks following any trial vaccination (except Diphtheria, Tetanus, Pertussis (DTP), Hib vaccine or Pneumo vaccine)
• Participation in another clinical trial at the same time.
• Contraindications to vaccination according to IMOVAX Polio™ leaflet.
• Subject plan to leave the study sites for at least three months after inclusion.